Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Alimta ® (pemetrexed for injection)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Alimta® (pemetrexed): Infusion Via Central Line Versus Peripheral IV
Lilly does not have any information available regarding infusion of pemetrexed via a central line versus peripheral IV.
Pemetrexed must be administered as an IV infusion.1
Lilly has not studied central line vs peripheral IV administration of pemetrexed.2
Clinical circumstances may be present which prevent a patient from having peripheral IV access. In the case of central line access only, the treating physician should make an appropriate clinical decision considering the risk/benefit, given that there is no information available regarding administration of pemetrexed via a central line IV.2
IV = intravenous
Lilly = Eli Lilly and Company
Date of Last Review: 04 September 2020